Viking Therapeutics (NASDAQ: VKTX) has been one of the few bright spots in the healthcare sector this year. The biotech's shares have stormed higher by almost 300% year to date on the back of its midstage weight-loss candidate, VK2735.

The lowdown is that VK2735 could be a top three weight-loss medication in terms of sales, according to some analyst estimates. That's a potentially incredible opportunity for risk-tolerant investors.

Image Source: Getty Images.

Continue reading

Source Fool.com